Narrow Band Imaging-assisted Transurethral Resection Reduces the Recurrence Risk of Non-muscle Invasive Bladder Cancer: A Systematic Review and Meta-analysis

Overview

Journal Oncotarget

Specialty Oncology

Date 2016 Nov 9

PMID 27823975

Citations 23

Authors

Weiting Kang

Zilian Cui

Qianqian Chen

Dong Zhang

Haiyang Zhang

Xunbo Jin

Affiliations

Soon will be listed here.

Abstract

Context: Compared with white light imaging (WLI) cystoscopy, narrow band imaging (NBI) cystoscopy could increase the visualization and detection of bladder cancer (BC) at the time of transurethral resection (TUR). NBI cystoscopy could increase the detection of BC, but it remains unclear whether narrow band imaging-assisted transurethral resection (NBI-TUR) could reduce the recurrence risk of non-muscle invasive bladder cancer (NMIBC). Several randomized clinical trials (RCTs) have recently tested the efficacy of NBI-TUR for NMIBC.

Objective: To perform a systematic review and meta-analysis of RCTs and evaluate the efficacy of NBI-TUR for NMIBC compared with white light imaging-assisted transurethral resection (WLI-TUR). The end point was recurrence risk.

Evidence Acquisition: A systematic review of PubMed, Medline, Ovid, Embase, Cochrane and Web of Science was performed in February 2016 and updated in July 2016.

Evidence Synthesis: Overall, six (n = 1084) of 278 trials were included. Three trials performed narrow band imaging-assisted electro-transurethral resection (NBI-ETUR), and two trials performed narrow band imaging-associated bipolar plasma vaporization (NBI-BPV). The last trial performed narrow band imaging-associated holmium laser resection (NBI-HLR). Statistical analysis was performed using Review Manager software (RevMan v.5.3; The Nordic Cochrane Center, Copenhagen, Denmark). The recurrence risk was compared by calculating risk ratios (RRs) with 95% confidence interval (CIs). Risk ratios with 95% CIs were calculated to compare 3-mo, 1-yr, and 2-yr survival rates. NBI-TUR was associated with improvements in the 3-mo recurrence risk (RR: 0.39; 95% CI, 0.26-0.60; p < 0.0001), 1-yr recurrence risk (RR: 0.52; 95% CI, 0.40-0.67; p < 0.00001) and 2-yr recurrence risk (RR: 0.60; 95% CI, 0.42-0.85; p = 0.004) compared with WLI-TUR.

Conclusions: Compared with WLI-TUR, NBI-TUR can reduce the recurrence risk of NMIBC. The results of this review will facilitate the appropriate application of NBI in NMIBC.

Citing Articles

Comparative Bladder Cancer Tissues Prediction Using Vision Transformer.

Sunnetci K, Oguz F, Ekersular M, Gulenc N, Ozturk M, Alkan A J Imaging Inform Med. 2024; .

PMID: 39455543 DOI: 10.1007/s10278-024-01228-1.

Optimizing cystoscopy and TURBT: enhanced imaging and artificial intelligence.

Shkolyar E, Zhou S, Carlson C, Chang S, Laurie M, Xing L Nat Rev Urol. 2024; 22(1):46-54.

PMID: 38982304 DOI: 10.1038/s41585-024-00904-9.

Transurethral Resection of Bladder Tumor: Novel Techniques in a New Era.

Sun S, Wang H, Zhang X, Chen G Bladder (San Franc). 2023; 10:e21200009.

PMID: 38022709 PMC: 10668603. DOI: 10.14440/bladder.2023.865.

Clinical Evaluation of Two Non-Invasive Genetic Tests for Detection and Monitoring of Urothelial Carcinoma: Validation of UroVysion and Xpert Bladder Cancer Detection Test.

Kavcic N, Peric I, Zagorac A, Kokalj Vokac N Front Genet. 2022; 13:839598.

PMID: 35734425 PMC: 9208547. DOI: 10.3389/fgene.2022.839598.

Narrow band imaging versus white light cystoscopy alone for transurethral resection of non-muscle invasive bladder cancer.

Lai L, Tafuri S, Ginier E, Herrel L, Dahm P, Maisch P Cochrane Database Syst Rev. 2022; 4:CD014887.

PMID: 35393644 PMC: 8990285. DOI: 10.1002/14651858.CD014887.pub2.

References

Kolozsy Z . Histopathological "self control" in transurethral resection of bladder tumours. Br J Urol. 1991; 67(2):162-4. DOI: 10.1111/j.1464-410x.1991.tb15100.x. View

Moher D, Liberati A, Tetzlaff J, Altman D . Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009; 151(4):264-9, W64. DOI: 10.7326/0003-4819-151-4-200908180-00135. View

Cauberg E, Kloen S, Visser M, de la Rosette J, Babjuk M, Soukup V . Narrow band imaging cystoscopy improves the detection of non-muscle-invasive bladder cancer. Urology. 2010; 76(3):658-63. DOI: 10.1016/j.urology.2009.11.075. View

Divrik R, Yildirim U, Zorlu F, Ozen H . The effect of repeat transurethral resection on recurrence and progression rates in patients with T1 tumors of the bladder who received intravesical mitomycin: a prospective, randomized clinical trial. J Urol. 2006; 175(5):1641-4. DOI: 10.1016/S0022-5347(05)01002-5. View

Hafner C, Knuechel R, Zanardo L, Dietmaier W, Blaszyk H, Cheville J . Evidence for oligoclonality and tumor spread by intraluminal seeding in multifocal urothelial carcinomas of the upper and lower urinary tract. Oncogene. 2001; 20(35):4910-5. DOI: 10.1038/sj.onc.1204671. View

Grossman H, Gomella L, Fradet Y, Morales A, Presti J, Ritenour C . A phase III, multicenter comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of superficial papillary lesions in patients with bladder cancer. J Urol. 2007; 178(1):62-7. DOI: 10.1016/j.juro.2007.03.034. View

Zhu Y, Shen Y, Ye D, Wang C, Yao X, Zhang S . Narrow-band imaging flexible cystoscopy in the detection of clinically unconfirmed positive urine cytology. Urol Int. 2011; 88(1):84-7. DOI: 10.1159/000333119. View

Avritscher E, Cooksley C, Grossman H, Sabichi A, Hamblin L, Dinney C . Clinical model of lifetime cost of treating bladder cancer and associated complications. Urology. 2006; 68(3):549-53. DOI: 10.1016/j.urology.2006.03.062. View

Herr H . Narrow band imaging cystoscopy. Urol Oncol. 2011; 29(4):353-7. DOI: 10.1016/j.urolonc.2010.12.002. View

10.

Herr H, Donat S . A comparison of white-light cystoscopy and narrow-band imaging cystoscopy to detect bladder tumour recurrences. BJU Int. 2008; 102(9):1111-4. DOI: 10.1111/j.1464-410X.2008.07846.x. View

11.

Jocham D, Stepp H, Waidelich R . Photodynamic diagnosis in urology: state-of-the-art. Eur Urol. 2007; 53(6):1138-48. DOI: 10.1016/j.eururo.2007.11.048. View

12.

Fradet Y, Grossman H, Gomella L, Lerner S, Cookson M, Albala D . A comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of carcinoma in situ in patients with bladder cancer: a phase III, multicenter study. J Urol. 2007; 178(1):68-73. DOI: 10.1016/j.juro.2007.03.028. View

13.

Geavlete B, Multescu R, Georgescu D, Stanescu F, Jecu M, Geavlete P . Narrow band imaging cystoscopy and bipolar plasma vaporization for large nonmuscle-invasive bladder tumors--results of a prospective, randomized comparison to the standard approach. Urology. 2012; 79(4):846-51. DOI: 10.1016/j.urology.2011.08.081. View

14.

Goh A, Lerner S . Application of new technology in bladder cancer diagnosis and treatment. World J Urol. 2009; 27(3):301-7. DOI: 10.1007/s00345-009-0387-z. View

15.

Kobatake K, Mita K, Ohara S, Kato M . Advantage of transurethral resection with narrow band imaging for non-muscle invasive bladder cancer. Oncol Lett. 2015; 10(2):1097-1102. PMC: 4509371. DOI: 10.3892/ol.2015.3280. View

16.

Tatsugami K, Kuroiwa K, Kamoto T, Nishiyama H, Watanabe J, Ishikawa S . Evaluation of narrow-band imaging as a complementary method for the detection of bladder cancer. J Endourol. 2010; 24(11):1807-11. DOI: 10.1089/end.2010.0055. View

17.

Shen Y, Zhu Y, Ye D, Yao X, Zhang S, Dai B . Narrow-band imaging flexible cystoscopy in the detection of primary non-muscle invasive bladder cancer: a "second look" matters?. Int Urol Nephrol. 2011; 44(2):451-7. DOI: 10.1007/s11255-011-0036-5. View

18.

Kirkali Z, Chan T, Manoharan M, Algaba F, Busch C, Cheng L . Bladder cancer: epidemiology, staging and grading, and diagnosis. Urology. 2006; 66(6 Suppl 1):4-34. DOI: 10.1016/j.urology.2005.07.062. View

19.

Botteman M, Pashos C, Redaelli A, Laskin B, Hauser R . The health economics of bladder cancer: a comprehensive review of the published literature. Pharmacoeconomics. 2004; 21(18):1315-30. DOI: 10.1007/BF03262330. View

20.

Stanescu F, Geavlete B, Georgescu D, Jecu M, Moldoveanu C, Adou L . NBI - plasma vaporization hybrid approach in bladder cancer endoscopic management. J Med Life. 2014; 7(2):155-9. PMC: 4197500. View